Tolerability and Efficacy of Deucravacitinib in the Treatment of Refractory Psoriasis. The Planet, [S. l.], v. 9, n. 03, p. 213–218, 2026. DOI: 10.5281/zenodo.20387594. Disponível em: https://www.bdjournals.org/planet/article/view/1195. Acesso em: 15 jul. 2026.